<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02560441</url>
  </required_header>
  <id_info>
    <org_study_id>CH-LYM-005</org_study_id>
    <nct_id>NCT02560441</nct_id>
  </id_info>
  <brief_title>Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type</brief_title>
  <official_title>A Multicenter Phase II Trial to Evaluate the Safety and Efficacy of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Guangxi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Dayi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhangzhou Municipal Hospital of Fujian Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first Part: recruiting untreated ENKL patients with extensive stage I or limited stage II
      disease (only referring to patients with the invasion of Waldeyer's ring and cervical lymph
      nodes) . Patients are randomly divided into two arms, IPGDP regimen chemotherapy followed by
      radiotherapy or radiotherapy followed by IPGDP regimen chemotherapy. IPGDP regimen for both
      arms are 3 cycles. And the chemotherapy is repeated every 3 weeks..

      The second part: recruiting extensive stage II ,stage III-IV, relapsed or refractory ENKL
      patients. Patients receive 6 cycles of IPGDP regimen chemotherapy. And the chemotherapy is
      repeated every 3 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first Part: Patients in IPGDP regimen chemotherapy followed by radiotherapy arm receive 3
      cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1;
      gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2
      iv on days 3-6) chemotherapy. Then patients undergo radiotherapy. If the disease is
      considered to progress or as stable during chemotherapy, the patient will directly receive
      radiotherapy. Patients in another arm receive radiotherapy followed by IPGDP regimen
      chemotherapy. IPGDP regimen for both arms are 3 cycles, which is repeated every 3 weeks.

      The second Part: Patients receive 6 cycles of ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase
      2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5;
      dexamethasone 20mg/m2 iv on days 3-6. IPGDP regimen is repeated every 3 weeks. If the disease
      is considered to progress or as stable after 2 cycles or 4 cycles of chemotherapy, the
      patient will withdraw from this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type</condition>
  <arm_group>
    <arm_group_label>chemotherapy followed by radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients receive 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy followed by radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiotherapy followed by chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients receive radiotherapy followed by 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPGDP regimen chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients receive 6 cycles of ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6. 6 cycles, every 3 weeks one cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chemotherapy followed by radiotherapy</intervention_name>
    <arm_group_label>chemotherapy followed by radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>radiotherapy followed by chemotherapy</intervention_name>
    <arm_group_label>radiotherapy followed by chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPGDP regimen chemotherapy</intervention_name>
    <arm_group_label>IPGDP regimen chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven diagnosis of Extranodal Natural Killer/T-Cell Lymphoma, Nasal
             Type(ENKL)

          -  untreated ENKL patients of extensive stage I and limited stage II ( only referring to
             patients with the invasion of Waldeyer's ring and neck lymph node) confirmed by
             imaging examination; extensive stage II ,stage III-IV, relapsed or refractory ENKL
             patients confirmed by imaging examination

          -  age 18-65 years

          -  at least one measurable lesions

          -  Eastern Cooperative Oncology Group (ECOG) of 0 to 1

          -  a life expectancy of at least 12 weeks

          -  Adequate organ function including the following:

        Bone marrow: absolute neutrophil count (ANC) &gt;or equal to 1.5 * 109/L, platelets &gt;or equal
        to 100 *109/L, hemoglobin &gt; or equal to 9g/dL.

        Hepatic: bilirubin &lt; or equal to 2 x ULN; aspartate transaminase (AST) and alanine
        transaminase (ALT) &lt; or equal to 2.5 x ULN (AST, ALT &lt; or equal to 5 x ULN is acceptable if
        liver has been involved).

        Renal: serum creatinine &lt; or equal to 1.5 x ULN. Coagulation function :activated partial
        thromboplastin time &lt; or equal to 1.5 x ULN, fibrinogen &gt; or equal to 0.75 times of the
        lower limit of the normal value, INR &lt; or equal to 1.5 x ULN.

          -  informed consent signed by patients prior to commencement of the study

          -  pregnancy test of Women of childbearing must be negative at the beginning of 7 days
             before treatment; surgical sterilization or taking contraceptive measures during
             treatment and three months after the end of treatment for males.

        Exclusion Criteria:

          -  severe allergies to the investigational drugs

          -  patients who had received unauthorized drugs or drugs of other trials within 4 weeks
             prior to the study

          -  Severe or unstable systemic disease，serious neurological or psychiatric diseases
             including seizures or dementia

          -  organ function including the following: Bone marrow: absolute neutrophil count (ANC) ＜
             1.5 * 109/L, platelets＜100 *109/L, hemoglobin ＜ 9g/dL.

        Hepatic: bilirubin &gt; 2 x ULN; aspartate transaminase (AST) and alanine transaminase (ALT)
        &gt;2.5 x ULN (AST, ALT &gt; 5 x ULN is acceptable if liver has been involved).

        Renal: serum creatinine &gt; 1.5 x ULN. Abnormal Coagulation function : such as activated
        partial thromboplastin time prolonged &gt; 1.5 x ULN, fibrinogen &lt; 0.75 times of the lower
        limit of the normal value, increased INR &gt; 1.5 x ULN any other important clinical or
        laboratory abnormalities that are not appropriate for research

          -  Patients who had previously received treatment of this study, or withdrew from the
             study

          -  receiving any other anti-tumor therapy at the same time

          -  pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuankai Shi</last_name>
    <phone>87788293</phone>
    <email>syuankaipumc@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute/Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Guangxi</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiaxin Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhuan Gao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Dayi Hospital</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiaohua Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Province Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liping Su</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <last_update_submitted>January 1, 2018</last_update_submitted>
  <last_update_submitted_qc>January 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shi Yuankai</investigator_full_name>
    <investigator_title>vice president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

